查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587399

生物製藥契約製造市場規模、佔有率和趨勢分析報告：按供應商、按服務、按藥物類型、按類型、按業務規模、按治療領域、按地區和細分市場預測，2025-2030年

Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trend Analysis Report By Source, By Service, By Drug Type, By Type, By Scale of Operation, By Therapeutic Area, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

生物製藥契約製造市場的成長與趨勢：

Grand View Research, Inc.的最新報告顯示，到2030年，全球生物製藥契約製造市場規模預計將達到758億美元，2025年至2030年複合年成長率為11.1%。

生物製藥管道的成長和缺乏足夠的製造能力是推動聚合物製造商和契約製造組織 (CMO) 之間合作的兩個關鍵因素。契約製造正在擴大其服務組合，以滿足企業對監管標準和新服務的需求。然而，大流行也產生了負面影響，預算和資源被轉移到「新冠產品」上，而犧牲了其他治療領域正在開發的其​​他生技藥品計劃。

由於 CMO 採取的變革，預計在預測期內，公司對 CMO 生產生技藥品和生物相似藥的依賴將會增加。公司與 CMO 之間合作投資的增加以及不斷努力擴大其服務組合證明了這一點。生物製藥供應鏈強大，在冠狀病毒大流行期間，全球基本上未受到影響。生物製藥契約製造也看到了對 COVID-19 疫苗和治療藥物的需求增加。因此，未來市場蘊藏著許多機會。例如，2020年，Astra Zeneca和牛津生物醫學公司簽訂了為期一年的臨床和商業供應協議，用於生產Astra Zeneca的COVID-19候選疫苗AZD1222。

市場的未來成長高度依賴生物製藥、生物加工和合約服務產業提供的有前景的機會。生命科學領域灌裝和加工服務的擴展以及強勁的創業投資投資是預計推動市場發展的兩個關鍵機會。例如，2019年，上海海和生物製藥有限公司為大型抗癌藥物組合籌集了1.466億美元的創業投資，並與外包合作夥伴浙江九洲藥業有限公司進行了槓桿收購。

生物製藥契約製造市場報告亮點

  • 由於哺乳動物表現系統在生技藥品開發中的高度普及，到 2024 年，基於哺乳動物的生物製藥契約製造將佔據最大市場佔有率，約為 57.1%。
  • 由於高資本投資，特別是下游工藝，工藝開拓服務在 2024 年將佔據全球市場最大的收入佔有率。
  • 由於對生技藥品製造的高需求，生物製藥契約製造在該領域佔據主導地位。然而，由於生物相似藥的發展具有降低成本的好處，預計生物相似藥產業在預測期內將實現最快的複合年成長率。
  • 由於有有效的生技藥品開發法規結構，美國在 2024 年將佔據北美市場 34.3% 的巨大佔有率。
  • 亞太地區生物製藥契約製造市場正在以良好的速度成長，印度和中國等新興經濟體正在採取措施保持競爭力，預計將成為一個快速成長的地區。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章生物製藥契約製造市場的變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 產品平臺分析
  • 定價模式分析
  • 市場分析工具
    • 波特五力分析
    • PESTEL分析

第4章生物製藥契約製造市場：供應商估算及趨勢分析

  • 細分儀表板
  • 供應商波動分析
  • 供應商，2018-2030
  • 哺乳動物的
  • 非哺乳動物

第5章生物製藥契約製造市場：服務評估與趨勢分析

  • 細分儀表板
  • 服務波動分析
  • 按服務分類，2018-2030
  • 製程開發
    • 下游加工
    • 上游加工
  • 填充和整理操作
  • 分析和品管研究
  • 包裝和標籤

第6章 生物製藥契約製造市場：藥品種類預估及趨勢分析

  • 細分儀表板
  • 藥物類型變異分析
  • 依藥物類型，2018-2030
  • 生物製藥
    • 單株抗體
    • 重組蛋白
    • 疫苗
    • 反義、RNAi、分子治療
    • 其他
  • 生物相似藥

第7章 生物製藥契約製造市場：類型估計和趨勢分析

  • 細分儀表板
  • 類型變異分析
  • 按類型，2018-2030
  • 藥物成分
  • 成品藥

第8章生物製藥契約製造市場：業務規模估算及趨勢分析

  • 細分儀表板
  • 業務規模變化分析
  • 2018-2030年按業務規模分類
  • 臨床
  • 商業的

第9章生物製藥契約製造市場：治療領域的估算與趨勢分析

  • 細分儀表板
  • 治療區域變化分析
  • 依治療領域，2018-2030
  • 瘤
  • 自體免疫疾病
  • 感染疾病
  • 心血管疾病
  • 代謝性疾病
  • 神經病學
  • 其他

第10章生物製藥契約製造市場：區域估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 科威特

第11章競爭格局

  • 公司分類
    • 市場領導者
    • 新興企業
  • 2024 年企業市場分析（企業熱圖分析）
  • 公司簡介
    • Boehringer Ingelheim GmbH
    • Lonza
    • Inno Biologics Sdn Bhd
    • Rentschler Biotechnologies GmbH
    • JRS PHARMA
    • AGC Biologics
    • ProBioGen
    • FUJIFILM Diosynth Biotechnologies USA, Inc.
    • Toyobo Co. Ltd.
    • Samsung Biologics
    • Thermo Fisher Scientific, Inc.
    • Binex Co., Ltd.
    • WuXi Biologics
    • AbbVie, Inc.
    • ADMA Biologics, Inc.
    • Catalent, Inc
    • Cambrex Corporation
    • Pfizer Inc.
    • Siegfried Holding AG
Product Code: GVR-2-68038-698-1

Biopharmaceuticals Contract Manufacturing Market Growth & Trends:

The global biopharmaceuticals contract manufacturing market size is estimated to reach USD 75.80 billion by 2030, expanding at a CAGR of 11.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing biopharmaceutical pipeline and lack of adequate manufacturing capabilities are two key factors that are driving partnership between large molecule manufacturers and Contract Manufacturing Organizations (CMOs). Contract manufacturers are engaged in broadening their service portfolio to meet the companies' demands with respect to regulatory standards and new services. The pandemic has, however, also had some negative knock-on effects as budgets and resources are diverted to "COVID products" at the expense of other biologics projects in development for other therapeutic areas.

The reliance of companies on CMOs for the production of biologics and biosimilars is expected to rise during the forecast period as a consequence of changes adopted by the CMOs. This is evident through growing investment in collaborations of companies with CMOs as well as continuous efforts taken up for expanding the service portfolio. The supply chain of biopharmaceuticals remained robust and was largely unaffected worldwide during the coronavirus outburst. Also, biopharmaceutical contract manufacturers are observing increased demand related to COVID-19 vaccine and therapeutics. Thus, the future holds numerous opportunities for the market. For instance, in 2020, AstraZeneca and Oxford Biomedica signed a one-year clinical and commercial supply agreement for the manufacturing of AstraZeneca's COVID-19 vaccine candidate, AZD1222.

The future growth of the market is highly dependent on the promising opportunities offered by the biopharmaceutical industry, bioprocessing industry, and contract service industry. Expansion of fill-and-finish services and increasing robustness of venture capital investments for the life science sector are two important opportunities that are anticipated to drive the market. For instance, in 2019, Shanghai HaiHe Biopharma Co. Ltd. raised USD 146.6 million as venture capital for its large cancer drug portfolio, which it shall utilize along with its outsourcing partner Zhejiang Jiuzhou Pharmaceutical Co., Ltd.

Biopharmaceuticals Contract Manufacturing Market Report Highlights:

  • Mammalian-based biopharmaceutical contract manufacturing captured the largest market share about 57.1% in 2024 owing to the high penetration of mammalian expression systems for biologics development
  • Process development services held the largest revenue share in the global market in 2024., owing to high capital investment, especially in downstream process
  • Biologics contract manufacturing dominated its counterpart segment owing to higher demand for biologics production. However, The biosimilar segment is anticipated to register the fastest CAGR over the forecast period due to cost-saving advantages associated with biosimilars development
  • The presence of an effective regulatory framework for biologics development in the U.S. has resulted in a large share of the North America market of 34.3% in 2024
  • Asia Pacific biopharmaceuticals contract manufacturing market is growing at a lucrative pace and is expected to emerge as the fastest-growing geographical area for biopharmaceutical R&D and manufacturing owing to developing economies such as India and China incorporating developments to sustain the competition

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
      • 1.7.1.1. Approach 1: Commodity flow approach
    • 1.7.2. Volume price analysis (Model 2)
      • 1.7.2.1. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Biopharmaceuticals Contract Manufacturing Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers Analysis
      • 3.2.1.1. Rise in investment by CMOs for capacity expansion
      • 3.2.1.2. Commercial success of biopharmaceuticals and consequent increase in demand for biopharmaceuticals
      • 3.2.1.3. Notable growth of biologics approvals
      • 3.2.1.4. Robust biopharmaceuticals pipeline
      • 3.2.1.5. Cost and time-saving benefits offered by contract services
    • 3.2.2. Market Restraints Analysis
      • 3.2.2.1. Limited outsourcing amongst well-established biopharmaceutical manufacturer
      • 3.2.2.2. Managing Relationships
  • 3.3. Product Pipeline Analysis
  • 3.4. Pricing Model Analysis
  • 3.5. Market Analysis Tools
    • 3.5.1. Porter's Five Forces Analysis
    • 3.5.2. PESTEL Analysis

Chapter 4. Biopharmaceuticals Contract Manufacturing Market: Source Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Source Movement Analysis
  • 4.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Source, 2018-2030 (USD Million)
  • 4.4. Mammalian
    • 4.4.1. Mammalian Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Non-mammalian
    • 4.5.1. Non-mammalian Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Biopharmaceuticals Contract Manufacturing Market: Service Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Service Movement Analysis
  • 5.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Service, 2018-2030 (USD Million)
  • 5.4. Process Development
    • 5.4.1. Process Development Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. Downstream Processing
      • 5.4.2.1. Downstream Processing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Upstream Processing
      • 5.4.3.1. Upstream Processing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Fill & Finish Operations
    • 5.5.1. Fill & Finish Operations Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Analytical & QC Studies
    • 5.6.1. Analytical & QC Studies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Packaging & Labelling
    • 5.7.1. Packaging & Labelling Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Biopharmaceuticals Contract Manufacturing Market: Drug Type Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Drug Type Movement Analysis
  • 6.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Drug Type, 2018-2030 (USD Million)
  • 6.4. Biologics
    • 6.4.1. Biologics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Monoclonal Antibodies
      • 6.4.2.1. Monoclonal Antibodies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Recombinant proteins
      • 6.4.3.1. Recombinant Proteins Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Vaccines
      • 6.4.4.1. Vaccines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. Antisense, RNAi, & Molecular Therapy
      • 6.4.5.1. Antisense, RNAi, & Molecular Therapy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Biosimilar
    • 6.5.1. Biosimilar Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Biopharmaceuticals Contract Manufacturing Market: Type Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Type Movement Analysis
  • 7.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Type, 2018-2030 (USD Million)
  • 7.4. Drug Substance
    • 7.4.1. Drug Substance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Finished Drug Product
    • 7.5.1. Finished Drug Product Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Biopharmaceuticals Contract Manufacturing Market: Scale of Operation Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Scale of Operation Movement Analysis
  • 8.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Scale of Operation, 2018-2030 (USD Million)
  • 8.4. Clinical
    • 8.4.1. Clinical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Commercial
    • 8.5.1. Commercial Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Biopharmaceuticals Contract Manufacturing Market: Therapeutic Area Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. Therapeutic Area Movement Analysis
  • 9.3. Biopharmaceuticals Contract Manufacturing: Market Estimates & Forecasts, by Therapeutic Area, 2018-2030 (USD Million)
  • 9.4. Oncology
    • 9.4.1. Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5. Autoimmune Diseases
    • 9.5.1. Autoimmune Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6. Infectious Diseases
    • 9.6.1. Infectious Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.7. Cardiovascular Diseases
    • 9.7.1. Cardiovascular Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.8. Metabolic Diseases
    • 9.8.1. Metabolic Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.9. Neurology
    • 9.9.1. Neurology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.10. Others
    • 9.10.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Biopharmaceuticals Contract Manufacturing Market: Regional Estimates & Trend Analysis

  • 10.1. Regional market share analysis, 2024 & 2030
  • 10.2. Regional Market Dashboard
  • 10.3. North America
    • 10.3.1. North America Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.3.2. U.S.
      • 10.3.2.1. Key Country Dynamics
      • 10.3.2.2. Competitive Scenario
      • 10.3.2.3. Regulatory Landscape
      • 10.3.2.4. U.S. Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.3.3. Canada
      • 10.3.3.1. Key Country Dynamics
      • 10.3.3.2. Competitive Scenario
      • 10.3.3.3. Regulatory Landscape
      • 10.3.3.4. Canada Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.3.4. Mexico
      • 10.3.4.1. Key Country Dynamics
      • 10.3.4.2. Competitive Scenario
      • 10.3.4.3. Regulatory Landscape
      • 10.3.4.4. Mexico Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.4. Europe
    • 10.4.1. Europe Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.2. U.K.
      • 10.4.2.1. Key Country Dynamics
      • 10.4.2.2. Competitive Scenario
      • 10.4.2.3. Regulatory Landscape
      • 10.4.2.4. U.K. Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.3. Germany
      • 10.4.3.1. Key Country Dynamics
      • 10.4.3.2. Competitive Scenario
      • 10.4.3.3. Regulatory Landscape
      • 10.4.3.4. Germany Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.4. France
      • 10.4.4.1. Key Country Dynamics
      • 10.4.4.2. Competitive Scenario
      • 10.4.4.3. Regulatory Landscape
      • 10.4.4.4. France Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.5. Italy
      • 10.4.5.1. Key Country Dynamics
      • 10.4.5.2. Competitive Scenario
      • 10.4.5.3. Regulatory Landscape
      • 10.4.5.4. Italy Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.6. Spain
      • 10.4.6.1. Key Country Dynamics
      • 10.4.6.2. Competitive Scenario
      • 10.4.6.3. Regulatory Landscape
      • 10.4.6.4. Spain Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.7. Denmark
      • 10.4.7.1. Key Country Dynamics
      • 10.4.7.2. Competitive Scenario
      • 10.4.7.3. Regulatory Landscape
      • 10.4.7.4. Denmark Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.8. Sweden
      • 10.4.8.1. Key Country Dynamics
      • 10.4.8.2. Competitive Scenario
      • 10.4.8.3. Regulatory Landscape
      • 10.4.8.4. Sweden Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.9. Norway
      • 10.4.9.1. Key Country Dynamics
      • 10.4.9.2. Competitive Scenario
      • 10.4.9.3. Regulatory Landscape
      • 10.4.9.4. Norway Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.5. Asia Pacific
    • 10.5.1. Asia Pacific Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.5.2. China
      • 10.5.2.1. Key Country Dynamics
      • 10.5.2.2. Competitive Scenario
      • 10.5.2.3. Regulatory Landscape
      • 10.5.2.4. China Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.5.3. Japan
      • 10.5.3.1. Key Country Dynamics
      • 10.5.3.2. Competitive Scenario
      • 10.5.3.3. Regulatory Landscape
      • 10.5.3.4. Japan Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.5.4. India
      • 10.5.4.1. Key Country Dynamics
      • 10.5.4.2. Competitive Scenario
      • 10.5.4.3. Regulatory Landscape
      • 10.5.4.4. India Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.5.5. South Korea
      • 10.5.5.1. Key Country Dynamics
      • 10.5.5.2. Competitive Scenario
      • 10.5.5.3. Regulatory Landscape
      • 10.5.5.4. South Korea Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.5.6. Australia
      • 10.5.6.1. Key Country Dynamics
      • 10.5.6.2. Competitive Scenario
      • 10.5.6.3. Regulatory Landscape
      • 10.5.6.4. Australia Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.5.7. Thailand
      • 10.5.7.1. Key Country Dynamics
      • 10.5.7.2. Competitive Scenario
      • 10.5.7.3. Regulatory Landscape
      • 10.5.7.4. Thailand Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.6. Latin America
    • 10.6.1. Latin America Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.6.2. Brazil
      • 10.6.2.1. Key Country Dynamics
      • 10.6.2.2. Competitive Scenario
      • 10.6.2.3. Regulatory Landscape
      • 10.6.2.4. Brazil Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.6.3. Argentina
      • 10.6.3.1. Key Country Dynamics
      • 10.6.3.2. Competitive Scenario
      • 10.6.3.3. Regulatory Landscape
      • 10.6.3.4. Argentina Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.7. Middle East and Africa
    • 10.7.1. Middle East and Africa Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.7.2. Saudi Arabia
      • 10.7.2.1. Key Country Dynamics
      • 10.7.2.2. Competitive Scenario
      • 10.7.2.3. Regulatory Landscape
      • 10.7.2.4. Saudi Arabia Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.7.3. UAE
      • 10.7.3.1. Key Country Dynamics
      • 10.7.3.2. Competitive Scenario
      • 10.7.3.3. Regulatory Landscape
      • 10.7.3.4. UAE Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.7.4. South Africa
      • 10.7.4.1. Key Country Dynamics
      • 10.7.4.2. Competitive Scenario
      • 10.7.4.3. Regulatory Landscape
      • 10.7.4.4. South Africa Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.7.5. Kuwait
      • 10.7.5.1. Key Country Dynamics
      • 10.7.5.2. Competitive Scenario
      • 10.7.5.3. Regulatory Landscape
      • 10.7.5.4. Kuwait Biopharmaceuticals Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Company Categorization
    • 11.1.1. Market Leaders
    • 11.1.2. Emerging Players
  • 11.2. Company Market Position Analysis, 2024 (Company Heat Map Analysis)
  • 11.3. Company Profiles
    • 11.3.1. Boehringer Ingelheim GmbH
      • 11.3.1.1. Participant's Overview
      • 11.3.1.2. Financial Performance
      • 11.3.1.3. Service Benchmarking
      • 11.3.1.4. Strategic Initiatives
    • 11.3.2. Lonza
      • 11.3.2.1. Participant's Overview
      • 11.3.2.2. Financial Performance
      • 11.3.2.3. Service Benchmarking
      • 11.3.2.4. Strategic Initiatives
    • 11.3.3. Inno Biologics Sdn Bhd
      • 11.3.3.1. Participant's Overview
      • 11.3.3.2. Financial Performance
      • 11.3.3.3. Service Benchmarking
      • 11.3.3.4. Strategic Initiatives
    • 11.3.4. Rentschler Biotechnologies GmbH
      • 11.3.4.1. Participant's Overview
      • 11.3.4.2. Financial Performance
      • 11.3.4.3. Service Benchmarking
      • 11.3.4.4. Strategic Initiatives
    • 11.3.5. JRS PHARMA
      • 11.3.5.1. Participant's Overview
      • 11.3.5.2. Financial Performance
      • 11.3.5.3. Service Benchmarking
      • 11.3.5.4. Strategic Initiatives
    • 11.3.6. AGC Biologics
      • 11.3.6.1. Participant's Overview
      • 11.3.6.2. Financial Performance
      • 11.3.6.3. Service Benchmarking
      • 11.3.6.4. Strategic Initiatives
    • 11.3.7. ProBioGen
      • 11.3.7.1. Participant's Overview
      • 11.3.7.2. Financial Performance
      • 11.3.7.3. Service Benchmarking
      • 11.3.7.4. Strategic Initiatives
    • 11.3.8. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
      • 11.3.8.1. Participant's Overview
      • 11.3.8.2. Financial Performance
      • 11.3.8.3. Service Benchmarking
      • 11.3.8.4. Strategic Initiatives
    • 11.3.9. Toyobo Co. Ltd.
      • 11.3.9.1. Participant's Overview
      • 11.3.9.2. Financial Performance
      • 11.3.9.3. Service Benchmarking
      • 11.3.9.4. Strategic Initiatives
    • 11.3.10. Samsung Biologics
        • 11.3.10.1.1. Participant's Overview
      • 11.3.10.2. Financial Performance
      • 11.3.10.3. Service Benchmarking
      • 11.3.10.4. Strategic Initiatives
    • 11.3.11. Thermo Fisher Scientific, Inc.
      • 11.3.11.1. Participant's Overview
      • 11.3.11.2. Financial Performance
      • 11.3.11.3. Service Benchmarking
      • 11.3.11.4. Strategic Initiatives
    • 11.3.12. Binex Co., Ltd.
      • 11.3.12.1. Participant's Overview
      • 11.3.12.2. Financial Performance
      • 11.3.12.3. Service Benchmarking
      • 11.3.12.4. Strategic Initiatives
    • 11.3.13. WuXi Biologics
      • 11.3.13.1. Participant's Overview
      • 11.3.13.2. Financial Performance
      • 11.3.13.3. Service Benchmarking
      • 11.3.13.4. Strategic Initiatives
    • 11.3.14. AbbVie, Inc.
      • 11.3.14.1. Participant's Overview
      • 11.3.14.2. Financial Performance
      • 11.3.14.3. Service Benchmarking
      • 11.3.14.4. Strategic Initiatives
    • 11.3.15. ADMA Biologics, Inc.
      • 11.3.15.1. Participant's Overview
      • 11.3.15.2. Financial Performance
      • 11.3.15.3. Service Benchmarking
      • 11.3.15.4. Strategic Initiatives
    • 11.3.16. Catalent, Inc
      • 11.3.16.1. Participant's Overview
      • 11.3.16.2. Financial Performance
      • 11.3.16.3. Service Benchmarking
      • 11.3.16.4. Strategic Initiatives
    • 11.3.17. Cambrex Corporation
      • 11.3.17.1. Participant's Overview
      • 11.3.17.2. Financial Performance
      • 11.3.17.3. Service Benchmarking
      • 11.3.17.4. Strategic Initiatives
    • 11.3.18. Pfizer Inc.
      • 11.3.18.1. Participant's Overview
      • 11.3.18.2. Financial Performance
      • 11.3.18.3. Service Benchmarking
      • 11.3.18.4. Strategic Initiatives
    • 11.3.19. Siegfried Holding AG
      • 11.3.19.1. Participant's Overview
      • 11.3.19.2. Financial Performance
      • 11.3.19.3. Service Benchmarking
      • 11.3.19.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 4 Global Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 5 Global Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 6 Global Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 7 Global Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 8 Global Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 9 Global Biopharmaceutical Contract Manufacturing, by Region, 2018 - 2030 (USD Million)
  • Table 10 North America Biopharmaceutical Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 11 North America Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 12 North America Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 13 North America Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 14 North America Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 15 North America Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 16 North America Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 17 U.S. Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 18 U.S. Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 19 U.S. Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 20 U.S. Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 21 U.S. Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 22 U.S. Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 23 Canada Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 24 Canada Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 25 Canada Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 26 Canada Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 27 Canada Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 28 Canada Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 29 Mexico Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 30 Mexico Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 31 Mexico Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 32 Mexico Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 33 Mexico Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 34 Mexico Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 35 Europe Biopharmaceutical Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 36 Europe Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 37 Europe Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 38 Europe Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 39 Europe Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 40 Europe Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 41 Europe Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 42 Germany Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 43 Germany Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 44 Germany Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 45 Germany Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 46 Germany Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 47 Germany Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 48 UK Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 49 UK Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 50 UK Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 51 UK Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 52 UK Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 53 UK Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 54 France Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 55 France Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 56 France Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 57 France Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 58 France Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 59 France Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 60 Italy Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 61 Italy Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 62 Italy Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 63 Italy Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 64 Italy Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 65 Italy Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 66 Spain Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 67 Spain Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 68 Spain Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 69 Spain Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 70 Spain Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 71 Spain Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 72 Denmark Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 73 Denmark Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 74 Denmark Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 75 Denmark Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 76 Denmark Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 77 Denmark Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 78 Sweden Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 79 Sweden Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 80 Sweden Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 81 Sweden Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 82 Sweden Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 83 Sweden Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 84 Norway Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 85 Norway Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 86 Norway Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 87 Norway Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 88 Norway Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 89 Norway Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 90 Asia Pacific Biopharmaceutical Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 91 Asia Pacific Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 92 Asia Pacific Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 93 Asia Pacific Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 94 Asia Pacific Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 95 Asia Pacific Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 96 Asia Pacific Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 97 China Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 98 China Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 99 China Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 100 China Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 101 China Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 102 China Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 103 Japan Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 104 Japan Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 105 Japan Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 106 Japan Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 107 Japan Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 108 Japan Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 109 India Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 110 India Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 111 India Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 112 India Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 113 India Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 114 India Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 115 South Korea Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 116 South Korea Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 117 South Korea Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 118 South Korea Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 119 South Korea Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 120 South Korea Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 121 Australia Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 122 Australia Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 123 Australia Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 124 Australia Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 125 Australia Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 126 Australia Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 127 Thailand Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 128 Thailand Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 129 Thailand Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 130 Thailand Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 131 Thailand Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 132 Thailand Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 133 Latin America Biopharmaceutical Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 134 Latin America Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 135 Latin America Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 136 Latin America Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 137 Latin America Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 138 Latin America Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 139 Latin America Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 140 Brazil Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 141 Brazil Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 142 Brazil Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 143 Brazil Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 144 Brazil Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 145 Brazil Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 146 Argentina Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 147 Argentina Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 148 Argentina Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 149 Argentina Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 150 Argentina Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 151 Argentina Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 152 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Country, 2018 - 2030 (USD Million)
  • Table 153 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 154 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 155 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 156 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 157 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 158 Middle East & Africa Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 159 South Africa Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 160 South Africa Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 161 South Africa Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 162 South Africa Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 163 South Africa Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 164 South Africa Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 165 Saudi Arabia Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 166 Saudi Arabia Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 167 Saudi Arabia Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 168 Saudi Arabia Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 169 Saudi Arabia Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 170 Saudi Arabia Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 171 UAE Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 172 UAE Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 173 UAE Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 174 UAE Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 175 UAE Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 176 UAE Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 177 Kuwait Biopharmaceutical Contract Manufacturing, by Source, 2018 - 2030 (USD Million)
  • Table 178 Kuwait Biopharmaceutical Contract Manufacturing, by Service, 2018 - 2030 (USD Million)
  • Table 179 Kuwait Biopharmaceutical Contract Manufacturing, by Drug Type, 2018 - 2030 (USD Million)
  • Table 180 Kuwait Biopharmaceutical Contract Manufacturing, by Type, 2018 - 2030 (USD Million)
  • Table 181 Kuwait Biopharmaceutical Contract Manufacturing, by Scale of Operation, 2018 - 2030 (USD Million)
  • Table 182 Kuwait Biopharmaceutical Contract Manufacturing, by Therapeutic Area, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Biopharmaceutical Contract Manufacturing, Market Segmentation
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Market Dynamics
  • Fig. 8 Market Driver Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Porter's Five Forces Analysis
  • Fig. 11 PESTEL Analysis, By SWOT Analysis
  • Fig. 12 Regional Marketplace: Key Takeaways
  • Fig. 13 Global Biopharmaceutical Contract Manufacturing, for Mammalian, 2018 - 2030 (USD Million)
  • Fig. 14 Global Biopharmaceutical Contract Manufacturing, for Non-mammalian, 2018 - 2030 (USD Million)
  • Fig. 15 Global Biopharmaceutical Contract Manufacturing, for Process Development, 2018 - 2030 (USD Million)
  • Fig. 16 Global Biopharmaceutical Contract Manufacturing, for Downstream, 2018 - 2030 (USD Million)
  • Fig. 17 Global Biopharmaceutical Contract Manufacturing, for Upstream, 2018 - 2030 (USD Million)
  • Fig. 18 Global Biopharmaceutical Contract Manufacturing, for Fill & Finish Operations, 2018 - 2030 (USD Million)
  • Fig. 19 Global Biopharmaceutical Contract Manufacturing, for Analytical & QC Studies, 2018 - 2030 (USD Million)
  • Fig. 20 Global Biopharmaceutical Contract Manufacturing, for Packaging & Labelling & Labelling, 2018 - 2030 (USD Million)
  • Fig. 21 Global Biopharmaceutical Contract Manufacturing, for Others, 2018 - 2030 (USD Million)
  • Fig. 22 Global Biopharmaceutical Contract Manufacturing, for Biologics, 2018 - 2030 (USD Million)
  • Fig. 23 Global Biopharmaceutical Contract Manufacturing, for Monoclonal Antibodies (mAbs), 2018 - 2030 (USD Million)
  • Fig. 24 Global Biopharmaceutical Contract Manufacturing, for Recombinant Proteins, 2018 - 2030 (USD Million)
  • Fig. 25 Global Biopharmaceutical Contract Manufacturing, for Vaccines, 2018 - 2030 (USD Million)
  • Fig. 26 Global Biopharmaceutical Contract Manufacturing, for Antisense, RNAi, & Molecular Therapy, 2018 - 2030 (USD Million)
  • Fig. 27 Global Biopharmaceutical Contract Manufacturing, for Others, 2018 - 2030 (USD Million)
  • Fig. 28 Global Biopharmaceutical Contract Manufacturing, for Biosimilars, 2018 - 2030 (USD Million)
  • Fig. 29 Global Biopharmaceutical Contract Manufacturing, for Drug Substance, 2018 - 2030 (USD Million)
  • Fig. 30 Global Biopharmaceutical Contract Manufacturing, for Finished Drug Product, 2018 - 2030 (USD Million)
  • Fig. 31 Global Biopharmaceutical Contract Manufacturing, for Clinical, 2018 - 2030 (USD Million)
  • Fig. 32 Global Biopharmaceutical Contract Manufacturing, for Commercial, 2018 - 2030 (USD Million)
  • Fig. 33 Global Biopharmaceutical Contract Manufacturing, for Oncology, 2018 - 2030 (USD Million)
  • Fig. 34 Global Biopharmaceutical Contract Manufacturing, for Autoimmune Diseases, 2018 - 2030 (USD Million)
  • Fig. 35 Global Biopharmaceutical Contract Manufacturing, for Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig. 36 Global Biopharmaceutical Contract Manufacturing, for Cardiovascular Diseases, 2018 - 2030 (USD Million)
  • Fig. 37 Global Biopharmaceutical Contract Manufacturing, for Metabolic Diseases, 2018 - 2030 (USD Million)
  • Fig. 38 Global Biopharmaceutical Contract Manufacturing, for Neurology, 2018 - 2030 (USD Million)
  • Fig. 39 Global Biopharmaceutical Contract Manufacturing, for Others, 2018 - 2030 (USD Million)
  • Fig. 40 Regional Outlook, 2024 & 2030
  • Fig. 41 North America Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 U.S. Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Canada Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Mexico Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Europe Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 UK Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Germany Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 France Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Italy Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Spain Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Denmark Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Sweden Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Norway Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Asia Pacific Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 India Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 China Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Japan Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 South Korea Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Australia Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Thailand Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Latin America Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Brazil Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Argentina Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Middle East & Africa Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 South Africa Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Saudi Arabia Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 UAE Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Kuwait Biopharmaceutical Contract Manufacturing Market Estimates and Forecasts, 2018 - 2030 (USD Million)